References
- Clayton J. Chagas disease 101. Nature465, S4–S5 (2010).
- Clayton J. The promise of T. cruzi genomics. Nature465, S16–S17 (2010).
- Oliveira I, Torrico F, Muñoz J, Gascon J. Congenital transmission of Chagas disease: a clinical approach. Expert Rev. Anti Infect. Ther.8(8), 945–956 (2010).
- Alarcón de Noya B, Díaz-Bello Z, Colmenares C et al. Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas, Venezuela. J. Infect. Dis.201, 1308–1315 (2010).
- Gascon J, Bern C, Pinazo MJ. Chagas’ disease in Spain, the United States and other non-endemic countries. Acta Trop.115, 22–27 (2010).
- Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect. Dis.1, 92–100 (2001).
- Gascón J, Albajar P, Cañas E et al. Diagnosis, management and treatment of chronic Chagas’ heart disease in areas where Trypanosoma cruzi infection is not endemic. Rev. Esp. Cardiol.60, 285–293 (2007).
- Rezende J. Diagnóstico de las manifestaciones digestivas de la enfermedad de Chagas. Enfermedades Emergentes9, 22–27 (2007).
- Murcia L, Carrilero B, Muñoz MJ, Iborra MA, Segovia M. Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas’ disease: a prospective study in a non-disease-endemic country. J. Antimicrob. Chemother.65, 1759–1764 (2010).
- Solari A, Ortíz S, Soto A et al. Treatment of Trypanosoma cruzi-infected children with nifurtimox: a 3 year follow-up by PCR. J. Antimicrob. Chemother.48, 515–519 (2001).
- Pérez-Molina JA, Pérez-Ayala A, Moreno S, Fernández-González MC, Zamora J, López-Velez R. Use of benznidazole to treat chronic Chagas’ disease: a systematic review with a meta-analysis. J. Antimicrob. Chemother.64(6), 1139–1147 (2009).
- Marin-Neto JA, Rassi A Jr, Avezum A Jr et al. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem. Inst. Oswaldo Cruz.104(1), 319–324 (2009).
- Castro JA, de Mecca MM, Bartel LC. Toxic side effects of drugs used to treat Chagas’ disease (American trypanosomiasis). Hum. Exp. Toxicol.25(8), 471–479 (2006).
- World Health Organization. Control of Chagas disease. Second Report of the WHO Expert Committee. WHO Technical Reports Series. WHO, Geneva, Switzerland, 905, 1–109 (2002).
- Cancado JR. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev. Inst. Med. Trop. Sao Paulo44, 29–37 (2002).
- Galvão LMC, Nunes RMB, Cançado JR, Brener Z, Krettli AU. Lytic antibodies titre as means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans. R. Soc. Trop. Med. Hyg.87, 220–223 (1993).
- Meira WS, Galvão LM, Gontijo ED, Machado-Coelho GL, Norris KA, Chiari E. Use of the Trypanosoma cruzi recombinant complement regulatory protein to evaluate therapeutic efficacy following treatment of chronic chagasic patients. J. Clin. Microbiol.42(2), 707–712 (2004).
- Flechas ID, Cuellar A, Cucunubá ZM et al. Characterising the KMP-11 and HSP-70 recombinant antigens’ humoral immune response profile in chagasic patients. BMC Infect. Dis.9, 186 (2009).
- Urbina JA. Ergosterol biosynthesis and drug development for Chagas disease. Mem. Inst. Oswaldo Cruz.104(1), 311–318 (2009).
- Gerpe A, Odreman-Nunez I, Draper P et al. Heteroallyl-containing 5-nitrofuranes as new anti-Trypanosoma cruzi agents with a dual mechanism of action. Bioorg. Med. Chem.16, 569–577 (2008).
- Barr SC, Warner KL, Kornreic BG et al. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob. Agents Chemother.49(12), 5160–5161 (2005).
- Batista Dda G, Batista MM, de Oliveira GM et al. Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas’ disease treatment. Antimicrob. Agents Chemother.54(7), 2940–2952 (2010).
- Rodrigues J. Present situation and new strategies for Chagas’ disease chemotherapy – a proposal. Mem. Inst. Oswaldo Cruz.104(4), 549–554 (2009).